Jack Ma's Ant Group bets on AI medicine

# Ant Group Seeks Salvation in AI Medicine: How Fintech Giant Is Reshaping Life After IPO Collapse

Five years ago, Ant Group stood on the brink of collapse. Jack Ma's legendary IPO in November 2020 became a story of how state regulation could instantly wipe tens of billions of dollars off a company's stock market valuation. It seemed then that the fintech empire was condemned to play the role of an obedient financial service under strict oversight by Chinese authorities. But now Ant Group is making an unexpected move: the company is radically reorienting itself toward artificial intelligence-based healthcare. This is not simple diversification—it is an attempt at rebirth under a new guise in an expanding sector valued at $69 billion.

Ant Group's decision has the logic of a survivor. The fintech sector in China has become a battlefield between the state and business. After regulators imposed restrictions on microlending, digital wallets, and lending, the company lost its primary sources of growth. Investors have long demanded new strategies, but AI medicine is an unexpected turn that deserves attention. Healthcare remains one of the last segments where state control in China is less rigid, and demand is guaranteed. Medicine is aging before our eyes, doctors are in short supply, and technology can solve this problem. For Ant Group, this means an opportunity to repurpose its technological potential in a direction that will not encounter political obstacles.

The AI healthcare sector is developing rapidly, and Ant Group enters it not as a pioneer but as a serious player with capital and expertise. The company is investing in digital diagnostics—systems capable of analyzing medical images, identifying diseases at early stages, and suggesting treatments with accuracy comparable to an experienced physician. In parallel, a personalized medicine direction is developing, where AI learns to analyze patient genetic data, medical history, and offers individual treatment regimens. This is not utopia—such systems already operate in clinics worldwide, and Ant Group possesses the computational power to scale them across China.

For the industry, this means the battle for dominance in AI medicine will be not just technological but geopolitical. The US and Europe have invested tens of billions in this sector, but Chinese companies have the advantage of access to vast volumes of medical data and patient willingness to use digital solutions. Ant Group, possessing an ecosystem of payments, analytics, and cloud infrastructure, can create a closed system where doctors, patients, and pharmaceutical companies are linked by a single platform. This would be similar to what WeChat did for social networks in China.

The question remains whether Ant Group can avoid the fate that befell it in fintech. The regulator is already demonstrating interest in AI—the government is developing standards for its use in medicine. But unlike the financial sector, where every move is controlled by the central bank, medicine leaves more room for innovation. Ant Group is betting that technology that saves lives will be perceived favorably, even if it is controlled by a private company.

The transformation of Ant Group from a financial giant into a leader in AI medicine is more than just adaptation to regulation. It is an acknowledgment that the future belongs to companies that can apply artificial intelligence to universal human problems. If Ant Group succeeds, it will regain the status of innovator it possessed before that collapse. If it fails, it will become another example of how politics can rewrite the fate of a technology giant.